A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages E2207-E2215

  Halse, Johan ^a   Greenspan, Susan ^b   Cosman, Felicia ^c   Ellis, Graham ^d   Santora, Arthur ^e   Leung, Albert ^e   Heyden, Norman ^e   Samanta, Suvajit ^e   Doleckyj, Steven ^e   Rosenberg, Elizabeth ^e   Denker, Andrew E ^e  

^a Osteoporoseklinikken   (Norway)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d Helderberg Nature Reserve   (South Africa)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANABOLIC AGENT; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; CYCLOSPORIN; ENCALERET; GLUCOCORTICOID; HEPARIN; PARATHYROID HORMONE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; BENZOIC ACID DERIVATIVE; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; CALCIUM SENSING RECEPTOR; JTT 305; PROPANOLAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MORNING DOSAGE; MULTICENTER STUDY; NEPHROLITHIASIS; OSSIFICATION; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; VITAMIN SUPPLEMENTATION; ANTAGONISTS AND INHIBITORS; BLOOD; BONE REMODELING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

AGED; BENZOATES; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PROPANOLAMINES; RECEPTORS, CALCIUM-SENSING; TREATMENT OUTCOME;

EID: 84910007997     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4009     Document Type: Article

References (34)

1. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377: 1276-1287.
2. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357: 905-916.
3. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003;88: 5212-5220.
4. Preotact, parathyroid hormone. European Medicines Agency website. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000659/WC500041343.pdf. Accessed May 2013.
5. NeerRM, ArnaudCD, Zanchetta JR, et al. Effect of parathyroidhormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344: 1434-1441.
6. Forteo [Package Insert]. Indianapolis, IN: Eli Lily and Co; 2002.
7. Gatti D, Viapiana O, Idolazzi L, Fracassi E, RossiniM, Adami S. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab. 2011;96: 1555-1559.
8. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81: 239-297.
9. Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2011;96: 2441-2449.
10. Marie PJ. The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone. 2010;46: 571-576.
11. Kimura S, Nakagawa T, Matsuo Y, Ishida Y, Okamoto Y, Hayashi M. JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats. Eur J Pharmacol. 2011;668: 331-336.
12. Fukumoto S, Nakamura T, Nishizawa Y, Hayashi M, Matsumoto T. Randomized, single-blinded placebo-controlled study of a novel calcilytic, JTT-305, in patients with postmenopausal osteoporosis. J Bone Miner Res. 2009;24(Supp1 1).
13. Fukumoto S, Nakamura T, Nishizawa Y, Matsumotot T. Randomized, double-blinded placebo-controlled study of a novel calcilytic compound, JTT-305, in patients with postmenopausal osteoporosis. Bone. 2011;S76.
14. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem. 2008;54: 188-196.
15. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab. 1993; 77: 1046-1053.
16. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem. 2001;47: 694-702.
17. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79: 1693-1700.
18. LiangKY, Zeger SL. Longitudinal data analysis ofcontinuous and discrete responses for pre-post designs. Indian J Stat. 2000;62(Series B Pt. 1): 134-148.
19. Glover SJ, Eastell R, McCloskey EV, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009;45: 1053-1058.
20. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165: 1762-1768.
21. Blumsohn A, Marin F, Nickelsen T, et al. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int. 2011;22: 1935-1946.
22. Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab. 2005;90: 3970-3977.
23. Jamal SA, Goltzman D, Hanley DA, Papaioannou A, Prior JC, Josse RG. Nitrateuseandchangesinbonemineraldensity: theCanadianMulticentre Osteoporosis Study. Osteoporos Int. 2009;20: 737-744.
24. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebocontrolled, randomized study ofAMG785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26: 19-26.
25. Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res. 2012; 27: 255-262.
26. Cabal A, Mehta K, Ross DS, et al. A semi-Mechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans. J Bone Miner Metab. 2013;28(8): 1830-1836.
27. Satterwhite J, Heathman M, Miller PD, Marín F, Glass EV, Dobnig H. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int. 2010;87: 485-492.
28. Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2010;95: 151-158.
29. Caltabiano S, Dollery CT, Hossain M, et al. Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women. Bone. 2013;56: 154-162.
30. Xue Y, Xiao Y, Liu J, et al. The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice. Am J Physiol Endocrinol Metab. 2012; 302: E841-E851.
31. Christensen SE, Nissen PH, Vestergaard P, et al. Skeletal consequences of familial hypocalciuric hypercalcaemia vs. primary hyperparathyroidism. Clin Endocrinol (Oxf). 2009;71: 798-807.
32. Christensen SE, Nissen PH, Vestergaard P, et al. Plasma 25-hydroxyvitamin D, 1, 25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur J Endocrinol. 2008;159: 719-727.
33. Isaksen T, Nielsen CS, Christensen SE, Nissen PH, Heickendorff L, Mosekilde L. Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study. Calcif Tissue Int. 2011;89: 285-294.
34. Abugassa S, Nordenström J, Järhult J. Bone mineral density in patients with familial hypocalciuric hypercalcaemia (FHH). Eur J Surg. 1992;158: 397-402.